Your browser doesn't support javascript.
loading
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.
Baer, Constance; Kimura, Shunsuke; Rana, Mitra S; Kleist, Andrew B; Flerlage, Tim; Feith, David J; Chockley, Peter; Walter, Wencke; Meggendorfer, Manja; Olson, Thomas L; Cheon, HeeJin; Olson, Kristine C; Ratan, Aakrosh; Mueller, Martha-Lena; Foran, James M; Janke, Laura J; Qu, Chunxu; Porter, Shaina N; Pruett-Miller, Shondra M; Kalathur, Ravi C; Haferlach, Claudia; Kern, Wolfgang; Paietta, Elisabeth; Thomas, Paul G; Babu, M Madan; Loughran, Thomas P; Iacobucci, Ilaria; Haferlach, Torsten; Mullighan, Charles G.
Afiliación
  • Baer C; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Kimura S; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. shunsuke.kimura@stjude.org.
  • Rana MS; Protein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Kleist AB; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Flerlage T; Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Feith DJ; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Chockley P; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Walter W; Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Meggendorfer M; Department of Bone Marrow Transplantation & Cell Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Olson TL; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Cheon H; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Olson KC; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Ratan A; Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Mueller ML; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Foran JM; Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Janke LJ; Medical Scientist Training Program, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Qu C; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Porter SN; Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Pruett-Miller SM; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Kalathur RC; Medical Scientist Training Program, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Haferlach C; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Kern W; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Paietta E; Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.
  • Thomas PG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Babu MM; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Loughran TP; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Iacobucci I; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Haferlach T; Protein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Mullighan CG; MLL Munich Leukemia Laboratory, Munich, Germany.
Nat Genet ; 54(5): 637-648, 2022 05.
Article en En | MEDLINE | ID: mdl-35513723
ABSTRACT
Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16dim/CD56bright NK cells. Mechanistically, the mutations resulted in ligand-biased chemokine receptor signaling, with decreased internalization of the G-protein-coupled receptor (GPCR) for CCL22, CCR4, via impaired ß-arrestin recruitment. This resulted in increased cell chemotaxis in vitro, bidirectional crosstalk with the hematopoietic microenvironment and enhanced NK cell proliferation in vivo in transgenic human IL-15 mice. Somatic CCL22 mutations illustrate a unique mechanism of tumor formation in which gain-of-function chemokine mutations promote tumorigenesis by biased GPCR signaling and dysregulation of microenvironmental crosstalk.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Quimiocina CCL22 / Trastornos Linfoproliferativos Límite: Animals Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Quimiocina CCL22 / Trastornos Linfoproliferativos Límite: Animals Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Alemania